The RAS/RAF-MEK1/2-ERK1/2 signalling cascade is deregulated in approximately 50% of colorectal tumours, which drives tumour progression through constitutive ERK1/2 activity16–18. Here, MAPK3 is linked to colorectal neoplasm.